ArticleJournal of hepatocellular carcinoma2025
Survival Outcomes and Prognostic Factors of Systemic Therapy for Advanced Hepatocellular Carcinoma: A Multidisciplinary Clinic Experience from Saudi Arabia.
Article in Journal of hepatocellular carcinoma, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Characteristics of hepatocellular carcinoma in a Saudi tertiary care center: a 10-year retrospective study.Hepatic oncology · 2026Article
- Construction of a Preoperative Prediction Model for TACE Resistance in Primary Hepatocellular Carcinoma Based on Machine Learning Algorithms.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate survival outcomes and prognostic factors of systemic therapies in advanced hepatocellular carcinoma (HCC) within Saudi Arabia, addressing the limited regional data. Patients and Methods: A retrospective review of 670 HCC patients was utilized. 130 patients with advanced HCC who received first-line systemic therapy were identified, and data on demographics, tumor characteristics, treatment regimens, laboratory findings, and survival outcomes were collected. Treatment response and survival outcomes were evaluated using RECIST criteria and the Kaplan-Meier method, respectively. Results: Our population's mean age was 70.4, majority being males. Sorafenib was the most frequently used, then nivolumab and the atezolizumab-bevacizumab (Atezo+Bev) combination. Median overall survival (OS) varied by treatment: patients receiving Atezo+Bev showed the longest OS, followed by nivolumab and sorafenib. No statistically significant difference was observed in survival. Despite the small sample size, this trend suggests a potential OS benefit with Atezo+Bev, particularly in patients with advanced hepatic dysfunction. Furthermore, 39.1% of patients had elevated alpha-fetoprotein (AFP) levels and 26.8% had sarcopenia. Multivariate analysis highlighted the elevated neutrophil-to-lymphocyte ratio (NLR) as a significant predictor of worse survival, reinforcing its relevance as a prognostic marker in HCC. Although sarcopenia demonstrated an improved survival trend, it was not statistically significant. Adverse events were consistent, with elevated AST, anorexia, and fatigue frequently observed. Conclusion: This study illustrated Atezo+Bev's potential in improving OS in advanced HCC, with an elevated NLR identified as a key marker for poor prognosis. These findings support the need for prospective studies to confirm and expand regional insights into the management of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.